A breast implant infection can involve the incision, surrounding breast tissue, or the space around an implant. Warning signs include increasing redness, warmth, swelling, pain, fever, or new wound drainage. Treatment depends on the severity and location of the infection and may involve antibiotics, drainage, or surgery.
Think you may have an infection? Contact your surgical team immediately or seek emergency care — don't wait for a web form. See full guidance below ↓
For nonurgent questions only. If you suspect an infection, don't use this form — contact your surgical team or seek emergency care.
If you suspect an infection, contact your surgical team immediately for assessment. If you have confusion, shortness of breath, extreme pain, or feel severely ill, seek emergency care. Sepsis is a life-threatening response to infection that requires immediate treatment. Do not wait for a routine consultation or a response to an online form.
A breast implant infection can involve the incision, the surrounding breast tissue, or the space around the implant itself. Warning signs include increasing redness, warmth, swelling, pain, fever, chills, or new wound drainage. Infections do not all look the same, and they can occasionally develop years after surgery, not only in the early postoperative period. Evaluation is clinical, drawing on history, examination, imaging when needed, and microbiological or molecular testing when appropriate. Treatment is individualized and may involve antibiotics, drainage, or surgery, including implant removal in some cases.
Symptoms that should prompt contact with your surgical team include:
Breastcancer.org advises contacting the surgical team for a fever of 100.4°F or higher after reconstruction, even if other symptoms are absent.
Infections do not all look the same. Some present as a localized skin infection, while others involve a fluid collection or the deeper implant pocket. The appearance of the breast alone cannot establish how extensive the problem is.
Some discomfort and swelling can occur during recovery. The important step is to have unexpected or worsening changes assessed, rather than deciding from a photograph or a symptom checklist that they are normal.
Yes. Although infections often become apparent during the postoperative period, delayed infections can also occur months or years later.
New swelling years after surgery should not automatically be labeled an infection. Fluid collections, implant rupture, capsular contracture, and other implant-related conditions may need consideration. Rarely, delayed swelling or a mass can be associated with breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL, which requires a different diagnostic pathway.
Your provider should evaluate the timing, symptoms, implant history, and examination findings before deciding which tests are appropriate.
Risk depends on the operation and the patient's circumstances. Reconstructive surgery literature identifies smoking, higher body mass index, prior radiation or chemotherapy, and complications such as damaged skin, hematoma, or seroma as factors associated with infection. These findings should not be turned into one risk estimate for every augmentation patient.
An infection rate reported after mastectomy reconstruction is not interchangeable with a rate after cosmetic augmentation. Neither is comparable to the percentage of explant specimens with a positive molecular finding in Dr. Whitfield's study: these are different populations and different outcomes.
No. A scar capsule normally forms around a breast implant as part of the body's response to a foreign device. Capsular contracture occurs when that capsule becomes abnormally tight and can cause firmness, distortion, or pain.
Bacteria and biofilm are among the proposed contributors to some cases of capsular contracture. However, capsular contracture is not, by itself, proof of active infection, and its causes are not fully established.
These distinctions matter because a tight capsule, an acute infection, and a positive molecular test describe different findings. They should not be used interchangeably.
Evaluation starts with the clinical picture, not a single laboratory result. The severity of symptoms and the condition of the breast help determine whether the next step is medication, additional testing, drainage, or urgent surgery.
Your provider may consider:
A late fluid collection may require evaluation beyond microbiology. When BIA-ALCL is a concern, the workup can include cytology and CD30 testing. A bacterial test alone does not answer that question.
These terms describe different laboratory approaches.
Culture attempts to grow microorganisms from a sample. Molecular testing looks for genetic material. PCR amplifies selected genetic targets, while targeted next-generation sequencing can characterize microbial DNA in the sample. The laboratory workflow used in Dr. Whitfield's study included PCR amplification and targeted sequencing.
Important distinction: A positive DNA finding is meaningful information to discuss with your provider, but it does not by itself demonstrate that the organisms were alive, that they were causing an active infection, or that a mature biofilm was present. The study's molecular methods did not establish those endpoints.
Likewise, a negative culture does not automatically rule out infection. A clinical study of implant-related infections reported negative cultures in some clinically diagnosed cases and identified prior antibiotic treatment as a possible explanation. Your provider should interpret the result in context.
The purpose of testing is to contribute to a clinical decision. A report should be interpreted alongside symptoms, the examination, specimen collection, and other findings, not used as a stand-alone instruction to start antibiotics or remove an implant.
In a 2024 study coauthored by Dr. Robert Whitfield and published in Microorganisms, 694 capsule and tissue samples were submitted for molecular microbial profiling. Of those samples, 203, or approximately 29%, returned positive microbiological findings.
The samples were collected in a capsulectomy and explant setting. The laboratory workflow used targeted next-generation sequencing and included PCR-based steps. The published 29% result was reported for NGS microbial profiling, not as a separately reported PCR-only infection rate.
Among the most prominent bacterial DNA findings were Cutibacterium acnes and Staphylococcus epidermidis.
Source: Whitfield R, Tipton CD, Diaz N, Ancira J, Landry KS. Clinical Evaluation of Microbial Communities and Associated Biofilms with Breast Augmentation Failure. Microorganisms. 2024;12(9):1830. DOI: 10.3390/microorganisms12091830. [Reference 8]
It means that molecular profiling returned positive findings in approximately 29% of the submitted surgical samples in this study.
It does not mean:
This was a retrospective study of selected surgical specimens, not a population screening study. It did not report a matched asymptomatic comparison group or direct confirmation of organism viability. Those limitations are important when translating the result into patient education.
The research adds to the discussion about microbial DNA detected around breast implants and the questions it raises about implant complications. Further research is needed to determine which findings are clinically important and how they should inform care.
A biofilm is a community of microorganisms associated with a surrounding matrix that helps them adhere to a surface. Biofilm biology is relevant to medical devices because that structure can make established microbial communities harder to treat.
However, detecting DNA from organisms capable of forming biofilm is not the same as demonstrating an established biofilm in a particular specimen. Dr. Whitfield's study characterized molecular microbial findings; it did not directly measure biofilm architecture in each positive sample.
The distinction helps patients understand the research without assuming that every positive molecular result represents the same clinical problem.
Treatment is individualized. Important considerations include the depth and severity of the infection, tissue condition, the presence of a fluid collection, microbiological findings, and the response to initial treatment.
Selected mild infections may be treated with oral antibiotics and close follow-up. Moderate or severe infections may require intravenous antibiotics. There is no single antibiotic or route that is right for every patient.
Do not rely on another patient's prescription or an online medication list. Your treating clinician should select and reassess treatment for your situation.
An infected fluid collection, damaged tissue, a deeper pocket infection, or failure to improve may require drainage or an operation. Surgical treatment can include cleaning the pocket, removing nonviable tissue, and removing the implant when necessary.
Do not wait for an arbitrary number of days if symptoms are getting worse. Prompt treatment and close reassessment are important.
In selected cases, the surgical team may attempt to preserve the reconstruction through a salvage approach, which can include operative washout and implant exchange. Salvage is not always appropriate or successful. Other patients need implant removal to control the infection.
If an implant is removed, whether and when another implant should be placed is a separate decision after infection control and healing. There is no universal replacement timetable suitable for every patient.
Follow your surgical team's instructions for wound care, activity, bathing, drains, and prescribed medicines. Breastcancer.org emphasizes keeping the incision clean and dry as directed and avoiding soaking until the surgical team confirms that incisions and drain sites have healed sufficiently.
Report concerning changes promptly. Individual postoperative instructions take priority over a generic online recovery schedule.
This form is for nonurgent consultation requests only. It is not an emergency channel. If you may have an active infection, contact your surgical team immediately or seek urgent medical assessment.
The cited Microorganisms paper declared no conflicts of interest and no external funding. Several coauthors listed affiliations with RTL Genomics, MicroGen DX, the laboratory used for the study. Those affiliations should be considered alongside the paper's methods and results.
Not necessarily. A positive molecular result identifies genetic material. It does not, by itself, establish living organisms, active infection, or mature biofilm. In Dr. Whitfield's study, the measured result was molecular microbial detection in surgical specimens.
Not by itself. A negative culture needs to be interpreted in clinical context rather than treated as a definitive answer to every possible cause of symptoms.
No. Selected mild infections can respond to antibiotic treatment, while other cases need drainage, surgery, or implant removal. The treatment decision depends on the clinical findings and response, not simply the word “infection.”
The presentation of implant-related infection varies, and localized findings may be the main concern. Do not use the absence of fever as the sole reason to dismiss increasing redness, pain, swelling, or drainage.
No. The study described molecular microbial findings and explored characteristics of the positive specimens. It did not establish that those findings caused systemic symptoms or demonstrate a treatment benefit based on test positivity.
This page uses patient-safety information, peer-reviewed evidence, and Dr. Whitfield's published research. References support general education and do not replace individualized medical advice.
Dr. Robert Whitfield is a board-certified plastic surgeon in Austin, Texas, and a coauthor of the Microorganisms study discussed above. His clinical focus includes breast implant removal, capsulectomy, and revision breast surgery. Research findings are presented with their limitations and are not used as a stand-alone diagnosis or treatment directive.
Discussing Breast Implant Concerns With Dr. Whitfield
Dr. Robert Whitfield is a board-certified plastic surgeon in Austin, Texas, and a coauthor of the Microorganisms study discussed above. For nonurgent questions about implant removal or other implant concerns, you can request consultation information through the practice.
If you may have an active infection, contact your surgical team immediately or seek urgent medical assessment. This consultation request form is not an emergency service. For severe illness or signs of sepsis, seek emergency care.
This page provides general education and cannot diagnose an infection or determine which treatment is appropriate for an individual patient.